lorlatinib
Showing 1 - 25 of 28
Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)
Not yet recruiting
- Lung Cancer
- Non-small Cell Lung Cancer
- Lorlatinib
- +2 more
- (no location specified)
Jul 7, 2023
Stage III NSCLC, Surgery Trial in Guangzhou (Lorlatinib)
Not yet recruiting
- Stage III NSCLC
- Surgery
- Lorlatinib
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Feb 21, 2023
Non Small Cell Lung Cancer, Metastatic, Recurrent Trial in United States (Lorlatinib, Ramucirumab)
Recruiting
- Non Small Cell Lung Cancer
- +2 more
- Lorlatinib
- Ramucirumab
-
Middletown, New Jersey
- +5 more
Aug 17, 2023
Moderate Hepatic Impairment, Severe Hepatic Impairment, Healthy Volunteers Trial in Tustin, Tampa, Saint Paul (Lorlatinib)
Recruiting
- Moderate Hepatic Impairment
- +2 more
- Lorlatinib
-
Tustin, California
- +2 more
Dec 7, 2022
Non-Small-Cell Lung Cancer, NSCLC Trial in Nagoya, Barcelona, Taipei (Lorlatinib)
Recruiting
- Non-Small-Cell Lung Cancer
- NSCLC
- Lorlatinib
-
Nagoya, Aichi, Japan
- +2 more
Jul 21, 2022
Pediatric Neuroblastoma Treated With Lorlatinib
Completed
- Neuroblastoma
- lorlatinib
-
Philadelphia, Pennsylvania
- +10 more
Nov 17, 2022
Advanced or Metastatic ROS1-Positive NSCLC Trial in Guangzhou (Lorlatinib)
Recruiting
- Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
- Lorlatinib
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's hospital
May 31, 2022
Advanced NSCLC Trial in India (Lorlatinib)
Completed
- Advanced Non-Small Cell Lung Cancer
- Lorlatinib
-
New Delhi, Delhi, India
- +11 more
Sep 13, 2022
Nonsmall Cell Lung Cancer Trial in Goyang-Si (Lorlatinib)
Recruiting
- Nonsmall Cell Lung Cancer
- Lorlatinib
-
Goyang-Si, Gyeonggi-do, Korea, Republic ofNational Cancer Center
Apr 4, 2022
Non Small Cell Lung Cancer Metastatic Trial in France (Lorlatinib)
Recruiting
- Non Small Cell Lung Cancer Metastatic
- Lorlatinib
-
Aix-en-Provence, France
- +38 more
Aug 9, 2022
Cancer Medicines in Metastatic Non-small Cell Lung Cancer in
Not yet recruiting
- Non-Small Cell Lung Cancer
- lorlatinib
- +17 more
-
Oslo, NorwayPfizer Norway
Apr 17, 2023
Lorlatinib in ALK/ROS1 Metastatic NSCLC Compassionate Use
Recruiting
- Metastatic Non Small Cell Lung Cancer
- Lorlatinib
-
Santiago De Compostela, A Coruña, Spain
- +24 more
Jun 1, 2022
Carcinoma, Non-Small-Cell Lung Trial in Worldwide (Lorlatinib)
Recruiting
- Carcinoma
- Non-Small-Cell Lung
- Lorlatinib
-
Orange, California
- +31 more
Dec 6, 2022
Non Small Cell Lung Cancer Metastatic Trial in France (Lorlatinib)
Recruiting
- Non Small Cell Lung Cancer Metastatic
- Lorlatinib
-
Angers, France
- +31 more
Apr 12, 2022
Cancer, Advanced Solid Tumor Trial in Kettering (lorlatinib, encorafenib + binimetinib, talazoparib)
Recruiting
- Cancer
- Advanced Solid Tumor
- lorlatinib
- +4 more
-
Kettering, OhioKettering Health Network
Oct 14, 2022
Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement Trial in Boston (Lorlatinib, Crizotinib,
Recruiting
- Lung Cancer
- +6 more
- Lorlatinib
- +3 more
-
Boston, Massachusetts
- +1 more
Mar 7, 2021
ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase
Completed
- ALK-positive NSCLC
- crizotinib
- +4 more
-
Sollentuna, SwedenPfizer Innovations AB
Mar 14, 2022
free Survival and Evaluate Participant Experience for Metastatic
Active, not recruiting
- Anaplastic Lymphoma Kinase-positive
- Carcinoma Non-small-cell Lung
- Brigatinib
- +4 more
-
Maynard, MassachusettsEmpiraMed, Inc.
Feb 28, 2022
NSCLC (NSCLC) Trial in Boston (Lorlatinib)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- Lorlatinib
-
Boston, MassachusettsMassachusetts general Hospital
Mar 7, 2021
NSCLC Trial in China (Lorlatinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Lorlatinib
-
Hefei, Anhui, China
- +20 more
Sep 27, 2021
Trial (Lorlatinib)
Approved for marketing
- Lorlatinib
- (no location specified)
May 13, 2020
Ganglioneuroblastoma, Neuroblastoma Trial in Canada, Puerto Rico, United States (procedure, drug, biological, radiation)
Recruiting
- Ganglioneuroblastoma
- Neuroblastoma
- Autologous Hematopoietic Stem Cell Transplantation
- +18 more
-
Birmingham, Alabama
- +158 more
Sep 14, 2022
NSCLC Trial in Worldwide (Lorlatinib, Crizotinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Lorlatinib
- Crizotinib
-
Altamonte Springs, Florida
- +164 more
May 27, 2022